KBP 5074

Drug Profile

KBP 5074

Alternative Names: KBP-5074

Latest Information Update: 21 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator KBP Biosciences
  • Class Antihypertensives
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Renal hypertension

Most Recent Events

  • 26 Oct 2017 Phase-I clinical trials in Renal hypertension (In volunteers) in USA (PO,Tablet) (NCT03340753)
  • 26 Oct 2017 KBP Biosciences initiates enrolment in a phase I bioequivalence trial in healthy volunteers in USA (PO,Capsule) (NCT03340753)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top